TCGX Acquisition Corp. TCGX
10.03 USD 0.00 (-0.05%)
Nov 4, 2026, 10:50 AM EST
10.03 Day range 10.05
9.90 52-week range 18.91
- YTD
- +0.25%
- 1 year
- +0.25%
News
benzinga.com TriGemX Bio And TCGX Acquisition File Form S-4; Expect To Close Combination In Q1 2027 And Trade On Nasdaq Under Ticker Symbol 'TGEM' TriGemX Bio, Inc. ("TriGemX Bio"), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acquisition Corp. (NASDAQ:TCGX) ("TCGX"), a
businesswire.com TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Biotechnology--TriGemX Bio, Inc. (“TriGemX Bio”), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for…
benzinga.com TriGemX Bio To Go Public Through Merger With TCGX Acquisition, Plans Nasdaq Listing Under TGEM; Upon Closing, Combined Company Expected to Receive ~$246M Of Gross Proceeds Transaction Includes Concurrent $160 million Private Investment in Public Equity (PIPE) Financing and Expected Gross Proceeds of Approximately $246 millionTriGemX Bio, a biotechnology company focused…
businesswire.com TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Biotechnology--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX…